EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Abbisko Cayman's enterprise value is HK$-181.49 Mil.
Abbisko Cayman's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-449.53 Mil. Therefore, Abbisko Cayman's EV-to-EBITDA for today is 0.40.
The historical rank and industry rank for Abbisko Cayman's EV-to-EBITDA or its related term are showing as below:
HKSE:02256'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -0.67 Med: 1.01 Max: 1.5
Current: 0.39
During the past 5 years, the highest EV-to-EBITDA of Abbisko Cayman was 1.50. The lowest was -0.67. And the median was 1.01.
HKSE:02256's EV-to-EBITDA is ranked better than 85.81% of 451
companies
in the Biotechnology industry
Industry Median: 9.15
vs HKSE:02256: 0.39
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Abbisko Cayman EV-to-EBITDA Historical Data
The historical data trend for Abbisko Cayman's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Abbisko Cayman's EV-to-EBITDA
For the Biotechnology subindustry, Abbisko Cayman's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abbisko Cayman's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Abbisko Cayman's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Abbisko Cayman's EV-to-EBITDA falls into.
Abbisko Cayman EV-to-EBITDA Calculation
Abbisko Cayman's EV-to-EBITDA for today is calculated as:
Abbisko Cayman's current Enterprise Value is HK$-181.49 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Abbisko Cayman's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-449.53 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Abbisko Cayman's PE Ratio for today is calculated as:
Abbisko Cayman's share price for today is HK$3.03.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Abbisko Cayman's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.733.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Abbisko Cayman's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Abbisko Cayman Ltd is a investment holding company it operates through its subsidiaries which is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. The company has only one business segment which is the development of innovative medicines.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:02256 has been successfully added to your